Innovative Strategy toward Mutant CFTR Rescue in Cystic Fibrosis: Design and Synthesis of Thiadiazole Inhibitors of the E3 Ligase RNF5

In cystic fibrosis (CF), deletion of phenylalanine 508 (F508del) in the CF transmembrane conductance regulator (CFTR) is associated to misfolding and defective gating of the mutant channel. One of the most promising CF drug targets is the ubiquitin ligase RNF5, which promotes F508del-CFTR degradation. Recently, the first ever reported inhibitor of RNF5 was discovered, i.e., the 1,2,4-thiadiazol-5-ylidene inh-2. Here, we designed and synthesized a series of new analogues to explore the structure-activity relationships (SAR) of this class of compounds. SAR efforts ultimately led to compound 16, which showed a greater F508del-CFTR corrector activity than inh-2, good tolerability, and no toxic side effects. Analogue 16 increased the basal level of autophagy similar to what has been described with RNF5 silencing. Furthermore, co-treatment with 16 significantly improved the F508del-CFTR rescue induced by the triple combination elexacaftor/tezacaftor/ivacaftor in CFBE41o- cells. These findings validate the 1,2,4-thiadiazolylidene scaffold for the discovery of novel RNF5 inhibitors and provide evidence to pursue this unprecedented strategy for the treatment of CF.

[1]  A. Cavalli,et al.  Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives , 2022, Journal of medicinal chemistry.

[2]  F. Zara,et al.  Targeting of Ubiquitin E3 Ligase RNF5 as a Novel Therapeutic Strategy in Neuroectodermal Tumors , 2022, Cancers.

[3]  F. Zara,et al.  Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment , 2021, International journal of molecular sciences.

[4]  G. Lukács,et al.  Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination , 2020, JCI insight.

[5]  M. Barreca,et al.  Current development of CFTR potentiators in the last decade. , 2020, European journal of medicinal chemistry.

[6]  M. Conese,et al.  The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis , 2020, Expert opinion on drug discovery.

[7]  Michelle Condren,et al.  Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy. , 2020, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[8]  Sheridan M. Hoy.  Elexacaftor/Ivacaftor/Tezacaftor: First Approval , 2019, Drugs.

[9]  C. Teneback,et al.  Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial , 2019, The Lancet.

[10]  E. Schneider-Futschik,et al.  Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of in Vitro Pharmacology and Clinical Translation. , 2019, ACS pharmacology & translational science.

[11]  Qingzeng Sun,et al.  Ubiquitin ligase RNF5 serves an important role in the development of human glioma , 2019, Oncology letters.

[12]  Paolo Scudieri,et al.  An overview on chemical structures as ΔF508-CFTR correctors. , 2019, European journal of medicinal chemistry.

[13]  I. Sermet-Gaudelus,et al.  Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine , 2019, Front. Pharmacol..

[14]  N. Vij,et al.  Adapting Proteostasis and Autophagy for Controlling the Pathogenesis of Cystic Fibrosis Lung Disease , 2019, Front. Pharmacol..

[15]  M. Gentzsch,et al.  Ion Channel Modulators in Cystic Fibrosis , 2018, Chest.

[16]  R. Ravazzolo,et al.  Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia. , 2018, Cell chemical biology.

[17]  V. Villella,et al.  Cellular proteostasis: a new twist in the action of thymosin α1 , 2018, Expert opinion on biological therapy.

[18]  G. Kroemer,et al.  Thymosin α1 represents a potential potent single molecule-based therapy for cystic fibrosis , 2017, Nature Medicine.

[19]  F. Liu,et al.  Fatty Acid Cysteamine Conjugates as Novel and Potent Autophagy Activators That Enhance the Correction of Misfolded F508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). , 2017, Journal of medicinal chemistry.

[20]  R. Ravazzolo,et al.  Genetic Inhibition Of The Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated To F508del Cystic Fibrosis Mutation , 2015, Scientific Reports.

[21]  Jinglan Zhou,et al.  Discovery of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator. , 2014, Journal of medicinal chemistry.

[22]  M. Maiuri,et al.  Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation , 2014, Autophagy.

[23]  S. McColley,et al.  A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. , 2014, The Lancet. Respiratory medicine.

[24]  P. Linsdell.  Functional architecture of the CFTR chloride channel , 2014, Molecular membrane biology.

[25]  William L. Jorgensen,et al.  Characterization of Biaryl Torsional Energetics and its Treatment in OPLS All-Atom Force Fields , 2013, J. Chem. Inf. Model..

[26]  G. Lukács,et al.  Mechanism-based corrector combination restores ΔF508-CFTR folding and function , 2013, Nature Chemical Biology.

[27]  V. Nizet,et al.  Regulation of ATG4B Stability by RNF5 Limits Basal Levels of Autophagy and Influences Susceptibility to Bacterial Infection , 2012, PLoS genetics.

[28]  A S Verkman,et al.  CFTR: folding, misfolding and correcting the ΔF508 conformational defect. , 2012, Trends in molecular medicine.

[29]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[30]  N. Pedemonte,et al.  Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling. , 2011, American journal of physiology. Cell physiology.

[31]  A. Ballabio,et al.  Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition , 2010, Nature Cell Biology.

[32]  D. Cyr,et al.  Mechanisms for rescue of correctable folding defects in CFTRDelta F508. , 2009, Molecular biology of the cell.

[33]  P. Negulescu,et al.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.

[34]  Alan S. Verkman,et al.  Chloride channels as drug targets , 2009, Nature Reviews Drug Discovery.

[35]  P. Farrell,et al.  The prevalence of cystic fibrosis in the European Union. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[36]  Richard I. Morimoto,et al.  Adapting Proteostasis for Disease Intervention , 2008, Science.

[37]  Nicola Mongelli,et al.  NMR-based quality control approach for the identification of false positives and false negatives in high throughput screening. , 2006, Current drug discovery technologies.

[38]  C. Lipinski.  Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.

[39]  Y. Nagao,et al.  Synthesis and antibacterial activity of new 1beta-methylcarbapenems having the potential for intramolecular nonbonded S...O interactions. , 2001, Chemical & pharmaceutical bulletin.

[40]  S Grinstein,et al.  Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. , 1994, The EMBO journal.

[41]  Matthew P. Anderson,et al.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive , 1992, Nature.

[42]  Pascal Barbry,et al.  Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation , 1991, Nature.

[43]  L. Tsui,et al.  Erratum: Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA , 1989, Science.

[44]  Michelle Condren,et al.  Ivacaftor: a novel gene-based therapeutic approach for cystic fibrosis. , 2013, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[45]  Ana Martínez,et al.  New Synthetic Route to of 1,2,4-Thiadiazolines and 1,3-Thiazolines via Thiadiazolopyridinium Salts , 1996 .